Intravacc and DZNE Awarded EU Funding to Develop Vaccine against Genetic ALS Variant

Intravacc and the German Center for Neurogenerative Diseases (DZNE), have been awarded a funding of € 2.5 million from the European Union to further develop a prototype ALS vaccine, including process development, scale-up and toxicology study.